Surgery for Obesity and Related Diseases最新文献

{"title":"A randomized, double-blind, placebo-controlled trial of weight loss using liraglutide 3.0 mg for weight recurrence after Roux-en-Y gastric bypass","authors":"Holly F. Lofton M.D. ,&nbsp;Gabrielle Maranga M.P.H. ,&nbsp;Robert Hold P.A.-C. ,&nbsp;George Fielding M.D. ,&nbsp;Heekoung Youn R.N. ,&nbsp;Akash Gujral M.S. ,&nbsp;Sean Heffron M.D. ,&nbsp;Christine Fielding M.D.","doi":"10.1016/j.soard.2024.08.037","DOIUrl":"10.1016/j.soard.2024.08.037","url":null,"abstract":"<div><h3>Background</h3><div>Bariatric surgery, such as Roux-en-Y gastric bypass (RYGB) remains the gold standard for treating obesity. Most people regain weight from postsurgery nadir.</div></div><div><h3>Objectives</h3><div>Liraglutide 3.0 mg is approved for weight management. This study will examine the effects on liraglutide 3.0 mg on weight regain post-RYGB.</div></div><div><h3>Setting</h3><div>University Hospital, United States.</div></div><div><h3>Methods</h3><div>A 56-week, double-blind, placebo-controlled study was conducted in 132 subjects, who achieved ≥25% total body weight loss (TBWL) status-post-RYGB and regained ≥10% TBWL after reaching nadir weight (NW). Subjects 18–120 months post-RYGB were randomized to receive liraglutide 3.0 mg/d (n = 89) or placebo (n = 43) with lifestyle counseling regularly for 56 weeks. The co-primary endpoints were the proportion of subjects losing at least 5%, 10%, and 15% TBWL and achieving weight lower than their NW.</div></div><div><h3>Results</h3><div>53.4% of the placebo group and 65% of the liraglutide group completed the trial due to Severe acute respiratory syndrome coronavirus 2 pandemic. The change in %TBWL from baseline to 56-weeks was −8.8 (8.5, −29.2 to 9.7) and 1.1 (3.5, −7.9 to 5.99) in the liraglutide and placebo groups, respectively. 76% and 17% of subjects achieved ≥5% TBWL at 56 weeks in the liraglutide and placebo groups, respectively; 51% and 26.0% of the liraglutide group achieved ≥10% and ≥15% TBWL, respectively. None of the placebo group lost ≥10% TBWL. Twenty-one percent of subjects receiving liraglutide surpassed postoperative NW. No subjects on placebo met this goal. Nonserious adverse events occurred in 41.6% of subjects on liraglutide. Serious adverse events (SAE) occurred less often on liraglutide.</div></div><div><h3>Conclusions</h3><div>Liraglutide was significantly more effective than placebo in treating weight regain that occurs post-RYGB without increased SAE.</div></div>","PeriodicalId":49462,"journal":{"name":"Surgery for Obesity and Related Diseases","volume":"21 2","pages":"Pages 135-145"},"PeriodicalIF":3.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142484696","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Endoscopic bariatric and metabolic therapies and its effect on metabolic dysfunction-associated steatotic liver disease: a review of the current literature","authors":"Varun Aitharaju M.D. ,&nbsp;Jonathan Ragheb M.D. ,&nbsp;Stephen Firkins M.D. ,&nbsp;Roma Patel M.D. ,&nbsp;C. Roberto Simons-Linares M.D.","doi":"10.1016/j.soard.2024.09.012","DOIUrl":"10.1016/j.soard.2024.09.012","url":null,"abstract":"<div><div>Endoscopic bariatric and metabolic therapies (EBMTs) are minimally invasive endoscopic procedures that have shown to demonstrate significant weight loss in people with obesity. While abundant data support their positive effect on weight loss, there remains a notable dearth of information regarding their effects on metabolic dysfunction-associated steatotic liver disease (MASLD). As rates of type 2 diabetes and obesity have grown worldwide, so has the rate of MASLD. Therefore, addressing these knowledge gaps is crucial in improving liver health worldwide. In this review, we aim to provide the existing evidence delineating the effects of primary and secondary endoscopic bariatric therapies on MASLD and determine knowledge gaps requiring future study. Utilizing PubMed search with relevant keywords such as “endoscopic bariatric therapies,” “NAFLD” (nonalcoholic fatty liver disease), “MAFLD” (metabolic dysfunction-associated fatty liver disease), “MASLD” (metabolic dysfunction-associated steatotic liver disease), we gathered case reports, reviews, and retrospective analyses, evaluating their data and limitations. In our manuscript, we detail many primary and secondary endoscopic therapies and the literature available exploring their impact on liver health. This review demonstrates that primary EBMTs improve noninvasive liver markers, weight loss, and overall metabolic syndrome suggesting significant benefit in MASLD. There is, however, a significant lack of literature studying how primary endoscopic therapies compare amongst each other and how revisional therapies affect MASLD. We additionally offer suggestions for future research to deepen our understanding of EBMTs and their effects on MASLD.</div></div>","PeriodicalId":49462,"journal":{"name":"Surgery for Obesity and Related Diseases","volume":"21 2","pages":"Pages 175-182"},"PeriodicalIF":3.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142607859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Magnetic duodenoileal anastomosis with sleeve gastrectomy: a prospective multicenter study","authors":"Laurent Biertho M.D. ,&nbsp;Simon Marceau M.D. ,&nbsp;Mélanie Nadeau M.Sc. ,&nbsp;Stéfane Lebel M.D. ,&nbsp;François Julien M.D. ,&nbsp;André Tchernof Ph.D. ,&nbsp;Thomas Ransom M.D. ,&nbsp;Richard T. Spence M.D. ,&nbsp;James Ellesmere M.D.","doi":"10.1016/j.soard.2024.10.020","DOIUrl":"10.1016/j.soard.2024.10.020","url":null,"abstract":"<div><h3>Background</h3><div>Magnetic digestive anastomosis has the potential to reduce anastomotic complications and complexity. We report the 1-year results of a new surgical technique using Self-forming Neodymium magnet Anastomosis Procedure with Sleeve gastrectomy (SNAP-S; GI Windows).</div></div><div><h3>Methods</h3><div>This was a prospective, nonrandomized multicenter trial. Participants with type 2 diabetes (T2D) who met criteria for metabolic surgery were recruited. A dual-path duodenoileal anastomosis was created at 300 cm from the ileocecal valve using circular magnetic anastomosis. The proximal magnet was deployed by endoscopy and the distal one by laparoscopy. Sleeve gastrectomy was performed at the same time. Data are reported as mean ± standard deviation or percentage.</div></div><div><h3>Results</h3><div>Nineteen subjects with T2D were recruited (age 45 ± 9 years, body mass index 43 ± 5 kg/m², hemoglobin A1C 7.3 ± 1.3%). There was no conversion, mortality, or adverse event related to the magnetic anastomosis. Mean time for anastomosis creation was 32 ± 10 minutes. One patient was not implanted because of an inability to bring the ileum to the duodenum. Follow-up rate at 12 months was 95%. A total of 41 procedure-related adverse events were recorded during follow-up. Seven events in 4 subjects were considered serious. Total weight loss at 3, 6, and 12 months was 22 ± 19%, 28 ± 19%, and 31 ± 11%, respectively. Excess weight loss was 45 ± 14%, 59 ± 21%, and 78 ± 33%, respectively. All patients had an hemoglobin A1C ≤6.0% at 12 months with complete T2D remission in 78%.</div></div><div><h3>Conclusion</h3><div>The SNAP-S procedure is feasible with a low complication rate related to the anastomotic technique itself. The SNAP-S procedure provides significant weight loss and improvement of comorbidities. Additional prospective data are needed to better define the place of SNAP-S procedure.</div></div>","PeriodicalId":49462,"journal":{"name":"Surgery for Obesity and Related Diseases","volume":"21 2","pages":"Pages 166-174"},"PeriodicalIF":3.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142696152","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Racial disparities in the utilization and outcomes of robotic bariatric surgery: an 8-year analysis of Metabolic and Bariatric Surgery Accreditation Quality Improvement Program data","authors":"Qais AbuHasan M.D.,&nbsp;Payton M. Miller M.D.,&nbsp;Wendy S. Li M.D.,&nbsp;Charles P. Burney M.D., M.P.H.,&nbsp;Tarik K. Yuce M.D., M.S.,&nbsp;Dimitrios Stefanidis M.D., Ph.D.","doi":"10.1016/j.soard.2024.09.002","DOIUrl":"10.1016/j.soard.2024.09.002","url":null,"abstract":"<div><h3>Background</h3><div>Robotic surgery utilization has been increasing across surgical specialties; however, racial disparities in patient access to care and outcomes have been reported.</div></div><div><h3>Objectives</h3><div>In this study, we examined racial disparities in the utilization and outcomes of robotic bariatric surgery over an 8-year period.</div></div><div><h3>Setting</h3><div>Metabolic and Bariatric Surgery Accreditation Quality Improvement Program (MBSAQIP) centers of excellence across the United States.</div></div><div><h3>Methods</h3><div>The MBSAQIP database was used to identify adult patients who underwent robotic bariatric surgery between 2015 and 2022. Patients were stratified according to race and ethnicity into non-Hispanic White, non-Hispanic Black or African American (AA), Indigenous, Asian, and Hispanic patients. Multivariable analyses were used to assess predictors of robotic surgery use, odds of minor and major complications, prolonged length of stay (prolonged length of stay (pLOS): ≥3 days), readmissions, reoperations, and mortality within 30 days.</div></div><div><h3>Results</h3><div>Out of 1,288,359 patients included, robotic surgery was utilized in 196,314 patients (15.2%), with a mean age of 44 ± 12 years and 80.6% females. Rates of robotic surgery increased to 30% by 2022. Compared to White patients, Black/AA patients were more likely to undergo robotic surgery (adjusted odds ratio (aOR) = 1.22, 95% confidence interval (CI) = 1.21-1.24, <em>P</em> &lt; .001). The safety of robotic bariatric surgery improved for both White and Black patients with decreased odds of major complications, readmissions, reoperations, and pLOS over the study period. However, Black/AA patients were more likely to experience minor and major complications, readmissions and have pLOS compared with White patients in 2022 (aOR:1.26, 95% CI:1.19-1.34, <em>P</em> &lt; .001; aOR:1.22, 95% CI:1.06-1.41, <em>P</em> = .006; aOR:1.44, 95% CI:1.28-1.62, <em>P</em> &lt; .001; aOR:2.26, 95% CI:2.06-2.47, <em>P</em> &lt; .001, respectively).</div></div><div><h3>Conclusion</h3><div>The utilization of robotic bariatric surgery has increased significantly over the past 8 years with continued improvements in its safety profile. While Black/AA patients have improved access to robotic surgery, their clinical outcomes continue to be worse than those of White patients. Efforts to address racial disparities in bariatric surgery outcomes must remain a priority to achieve health equity.</div></div>","PeriodicalId":49462,"journal":{"name":"Surgery for Obesity and Related Diseases","volume":"21 2","pages":"Pages 158-165"},"PeriodicalIF":3.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142484701","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on: Endoscopic bariatric and metabolic therapies and its effect on MASLD: a review of the current literature","authors":"Donovan Hui M.D.,&nbsp;Thomas H. Shin M.D., Ph.D.","doi":"10.1016/j.soard.2024.10.029","DOIUrl":"10.1016/j.soard.2024.10.029","url":null,"abstract":"","PeriodicalId":49462,"journal":{"name":"Surgery for Obesity and Related Diseases","volume":"21 2","pages":"Pages 182-183"},"PeriodicalIF":3.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142635496","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on: Patients’ experience with preoperative use of anti-obesity medications and associations with bariatric surgery expectations","authors":"Sol Lee M.D.,&nbsp;Mélissa V. Wills M.D.,&nbsp;Matthew Kroh M.D.","doi":"10.1016/j.soard.2024.10.030","DOIUrl":"10.1016/j.soard.2024.10.030","url":null,"abstract":"","PeriodicalId":49462,"journal":{"name":"Surgery for Obesity and Related Diseases","volume":"21 2","pages":"Pages 115-116"},"PeriodicalIF":3.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142640525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"American Society for Metabolic and Bariatric Surgery literature review on risk factors, screening recommendations, and prophylaxis for marginal ulcers after metabolic and bariatric surgery","authors":"R. Wesley Vosburg M.D. ,&nbsp;Abdelrahman Nimeri M.D. ,&nbsp;Dan Azagury M.D. ,&nbsp;Brandon Grover M.D. ,&nbsp;Sabrena Noria M.D. ,&nbsp;Pavlos Papasavas M.D. ,&nbsp;Jonathan Carter M.D.","doi":"10.1016/j.soard.2024.10.013","DOIUrl":"10.1016/j.soard.2024.10.013","url":null,"abstract":"<div><h3>Background</h3><div>Marginal ulcers (MU) are a significant postoperative complication following anastomotic metabolic and bariatric surgeries including Roux-en-Y gastric bypass (RYGB), one-anastomosis gastric bypass (OAGB), and biliopancreatic diversion with duodenal switch (BPD/DS). This review summarizes current knowledge on MU risk factors, screening, and prophylactic strategies.</div></div><div><h3>Objectives</h3><div>The goal of this review is to examine technical and patient-related risk factors for MU, assess screening strategies, and recommend prophylactic approaches to reduce MU incidence after anastomotic metabolic and bariatric surgery (MBS).</div></div><div><h3>Setting</h3><div>A comprehensive review was conducted by members of the American Society for Metabolic and Bariatric Surgery (ASMBS) Clinical Issues Committee, based on available literature from 2000 to the present.</div></div><div><h3>Methods</h3><div>A systematic search was performed using Ovid MEDLINE and PubMed databases. Relevant studies were screened for inclusion. Technical and patient-related factors were evaluated, and recommendations for MU prevention were formulated.</div></div><div><h3>Results</h3><div>Several risk factors for MU were identified, including large gastric pouch size, circular stapled anastomoses, use of nonabsorbable sutures, smoking, nonsteroidal anti-inflammatory drugs use, and immunosuppression. While prophylactic proton pump inhibitor (PPI) therapy is widely recommended, its optimal duration remains debated. The role of <em>Helicobacter pylori</em> in MU development is not clearly defined.</div></div><div><h3>Conclusions</h3><div>Prophylactic PPI therapy for at least 3 months postsurgery significantly reduces the risk of MU. Risk stratification and individualized treatment plans are essential to minimize postoperative complications. Further research is needed to clarify the role of <em>H. pylori</em> and optimize prophylactic strategies.</div></div>","PeriodicalId":49462,"journal":{"name":"Surgery for Obesity and Related Diseases","volume":"21 2","pages":"Pages 101-108"},"PeriodicalIF":3.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142635486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Utilization patterns of glucagon like Peptide-1 receptor agonists prior to bariatric and metabolic surgery: a multicenter study","authors":"Shlomi Rayman M.D. ,&nbsp;Evyatar Morduch ,&nbsp;Anat Reiner-Benaim Ph.D. ,&nbsp;Netta-lee Catzman R.N., M.N. ,&nbsp;Idan Carmeli M.D. ,&nbsp;Dvir Froylich M.D. ,&nbsp;David Goitein","doi":"10.1016/j.soard.2024.09.010","DOIUrl":"10.1016/j.soard.2024.09.010","url":null,"abstract":"<div><h3>Background</h3><div>Glucagon-like-peptide-1 receptor agonists (G1RA) have gained popularity as a treatment for weight loss in patients who are overweight or obese, but their utilization patterns and impact on candidates for metabolic and bariatric surgery (MBS) remain understudied.</div></div><div><h3>Objective</h3><div>We aimed to investigate the prevalence, characteristics, and outcomes of patients with a history of G1RA utilization among MBS candidates.</div></div><div><h3>Setting</h3><div>Five high-volume MBS centers in Israel.</div></div><div><h3>Methods</h3><div>Data were collected retrospectively from February 1st, 2023, to September 30th, 2023. Demographic, clinical, and treatment data were analyzed to assess a history of G1RA use, associated factors, adverse events, and treatment outcomes.</div></div><div><h3>Results</h3><div>Four hundred thirty-four MBS candidates were included in the study. A history of G1RA utilization was obtained in 275 (63%) MBS candidates, with Liraglutide and Semaglutide being the most commonly used agents. Younger age, type 2 diabetes mellitus, dyslipidemia, and no previous MBS history were associated with a higher rate of G1RA utilization. With these medications, median maximal weight loss was 5.38 kg, and mean duration of use was 19 weeks. Patients using G1RA for ≥6 weeks experienced significantly greater weight loss compared to those using it for shorter periods (6.3 ± 6.43 vs 1.65 ± 1.69; <em>P</em> &lt; .001). GI-related adverse events were reported in 57.8% of patients. Over 95% of patients discontinued G1RA due to insufficient weight loss and/or adverse effects. Patients reaching the maximal recommended dose exhibited significantly greater weight loss versus patients who did not reach it for both Liraglutide (5.9 ± 4.98 kg vs. 3.9 ± 5.53 kg; <em>P</em> = .03) and Semaglutide (6.5 ± 7.8 kg vs. 2.5 ± 3.8 kg; <em>P</em> = .016).</div></div><div><h3>Conclusion</h3><div>Pre-MBS G1RA utilization and failure are prevalent among MBS candidates. Our study underscores the need for further research to understand the role of G1RA therapy in obesity management and the development of guidelines for its appropriate use in MBS candidates.</div></div>","PeriodicalId":49462,"journal":{"name":"Surgery for Obesity and Related Diseases","volume":"21 2","pages":"Pages 121-126"},"PeriodicalIF":3.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142635498","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Changes in pancreatic steatosis by computed tomography 24 months after sleeve gastrectomy in youth with severe obesity","authors":"Imen Becetti M.D. ,&nbsp;Ana Paola Lopez Lopez M.D. ,&nbsp;Francesca Galbiati M.D. ,&nbsp;Clarissa C. Pedreira M.D. ,&nbsp;Meghan Lauze B.S. ,&nbsp;Karen Olivar Carreno M.D. ,&nbsp;Florian A. Huber M.D. ,&nbsp;Olivier Bitoun M.D. ,&nbsp;Hang Lee Ph.D. ,&nbsp;Brian Carmine M.D. ,&nbsp;Vibha Singhal M.D., M.P.H. ,&nbsp;Madhusmita Misra M.D., M.P.H. ,&nbsp;Miriam A. Bredella M.D., M.B.A.","doi":"10.1016/j.soard.2024.08.034","DOIUrl":"10.1016/j.soard.2024.08.034","url":null,"abstract":"<div><h3>Background</h3><div>Pancreatic steatosis has been associated with obesity and the metabolic syndrome. Studies in adults have demonstrated improvement in pancreatic steatosis following sleeve gastrectomy (SG) with concomitant improvement in glucose homeostasis.</div></div><div><h3>Objectives</h3><div>To examine changes in pancreatic steatosis in youth with severe obesity 24 months following SG.</div></div><div><h3>Setting</h3><div>Academic hospital system.</div></div><div><h3>Methods</h3><div>Forty-seven youth (13–24 years) with severe obesity (37 females) were followed for 24 months; 23 had SG and 24 were nonsurgical (NS) controls. Attenuations of the pancreas and spleen were measured using computed tomography (CT) at baseline, 12- and 24-month follow-up. Subjects underwent magnetic resonance imaging (MRI) for subcutaneous and visceral adipose tissue (SAT, VAT), dual energy x-ray absorptiometry (DXA) for body composition, blood sampling for glycated hemoglobin (A1C), and fasting and postprandial insulin and glucose. Linear mixed effects (LMEs) models were used to compare within- and between-group changes over 24 months.</div></div><div><h3>Results</h3><div>At baseline, SG had higher body mass index (BMI) versus NS (<em>P</em> = .033). Over 24 months, significant reductions were noted in weight, BMI, VAT, SAT, fat mass (FM), and lean mass (LM) in the SG versus NS groups (<em>P</em> ≤ .0001). There was a significant 24-month decrease in pancreatic steatosis in the SG group (<em>P</em> = .006). In the whole group, 24-month reductions in pancreatic steatosis correlated with BMI and FM decreases. No associations were found between pancreatic steatosis and glucose homeostasis parameters.</div></div><div><h3>Conclusions</h3><div>Pancreatic steatosis measured by CT improved after SG in youth. Further studies are needed to understand the relationship between pancreatic steatosis and glucose homeostasis.</div></div>","PeriodicalId":49462,"journal":{"name":"Surgery for Obesity and Related Diseases","volume":"21 1","pages":"Pages 59-66"},"PeriodicalIF":3.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142368116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The relationship of decision regret with quality of life and comfort level in patients undergoing laparoscopic sleeve gastrectomy: a cross-sectional study","authors":"Tülay Kılınç Ph.D. ,&nbsp;Ayşegül Yayla Ph.D. ,&nbsp;Zeynep Karaman Özlü Ph.D. ,&nbsp;Duygu Balaban M.Sc.","doi":"10.1016/j.soard.2024.08.030","DOIUrl":"10.1016/j.soard.2024.08.030","url":null,"abstract":"<div><h3>Background</h3><div>Laparoscopic sleeve gastrectomy (SG) is one of the effective methods of weight loss. It is essential to determine patients' regret and predictive factors to improve their quality of life and comfort. No study has investigated decision regret and affecting factors in patients undergoing SG in Turkey.</div></div><div><h3>Objectives</h3><div>The study aimed to determine the relationship of decision regret with quality of life and comfort level in patients undergoing SG.</div></div><div><h3>Setting</h3><div>The research was carried out with patients who had undergone SG in a private hospital in the west of Turkey.</div></div><div><h3>Methods</h3><div>The research was conducted as a descriptive, correlational, and cross-sectional study. Data were collected between March and May 2023, and the study was completed with 286 patients. Data were collected using the Personal Information Form, Decision Regret Scale (DRS), Quality of Life Following Obesity Surgery Scale (QoL-OS), and Comfort Scale.</div></div><div><h3>Results</h3><div>Patients’ mean score on the DRS was 5.27 ± 13.41 (0-100), the total mean score on the QoL-OS-Biopsychosocial dimension was 79.57 ± 9.35 (18-90), the mean score on the QoL-OS-Complications dimension was 17.17 ± 4.60 (7-35), and the environmental comfort score average was 8.87 ± 2.23 (0-10). Patients’ decision regret was significantly affected by the QoL-OS-Biopsychosocial Area dimension in the first place (Beta = −.516; <em>P</em> &lt; .001), social comfort in the second place (Beta = −.278; <em>P</em> &lt; .001), postoperative weight gain in the third place (Beta = .221; <em>P</em> &lt; .001), and complication development in the fourth place (Beta = .163; <em>P</em> &lt; .001).</div></div><div><h3>Conclusions</h3><div>The study revealed that patients’ decision regret levels were very low up to 3 years after surgery and found that low postoperative quality of life and social comfort level, postoperative weight gain, and complications affected decision regret.</div></div>","PeriodicalId":49462,"journal":{"name":"Surgery for Obesity and Related Diseases","volume":"21 1","pages":"Pages 41-51"},"PeriodicalIF":3.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142376492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}